OBJECTIVES: We sought to evaluate the association between plasma levels of monocyte chemoattractant protein (MCP)-1 and the risk for subclinical atherosclerosis. BACKGROUND: Monocyte chemoattractant protein is a chemokine that recruits monocytes into the developing atheroma and may contribute to atherosclerotic disease development and progression. Plasma levels of MCP-1 are independently associated with prognosis in patients with acute coronary syndromes, but few population-based data are available from subjects in earlier stages of atherosclerosis. METHODS: In the Dallas Heart Study, a population-based probability sample of adults in Dallas County </=65 years old, plasma levels of MCP-1 were measured in 3,499 subjects and correlated with traditional cardiovascular risk factors, high-sensitivity C-reactive protein (hs-CRP), and coronary artery calcium (CAC) measured by electron beam computed tomography. RESULTS: Higher MCP-1 levels were associated with older age, white race, family history of premature coronary disease, smoking, hypertension, diabetes, hypercholesterolemia, and higher levels of hs-CRP (p < 0.01 for each). Similar associations were observed between MCP-1 and risk factors in the subgroup of participants without detectable CAC. Compared with the subjects in the lowest quartile of MCP-1, the odds of prevalent CAC (CAC score >/=10) for subjects in the second, third, and fourth quartiles were 1.30 (95% confidence interval [CI] 0.99 to 1.73), 1.60 (95% CI 1.22 to 2.11), and 2.02 (95% CI 1.54 to 2.63), respectively. The association between MCP-1 and CAC remained significant when adjusted for traditional cardiovascular risk factors, but not when further adjusted for age. CONCLUSIONS: In a large population-based sample, plasma levels of MCP-1 were associated with traditional risk factors for atherosclerosis, supporting the hypothesis that MCP-1 may mediate some of the atherogenic effects of these risk factors. These findings support the potential role of MCP-1 as a biomarker target for drug development.
OBJECTIVES: We sought to evaluate the association between plasma levels of monocyte chemoattractant protein (MCP)-1 and the risk for subclinical atherosclerosis. BACKGROUND: Monocyte chemoattractant protein is a chemokine that recruits monocytes into the developing atheroma and may contribute to atherosclerotic disease development and progression. Plasma levels of MCP-1 are independently associated with prognosis in patients with acute coronary syndromes, but few population-based data are available from subjects in earlier stages of atherosclerosis. METHODS: In the Dallas Heart Study, a population-based probability sample of adults in Dallas County </=65 years old, plasma levels of MCP-1 were measured in 3,499 subjects and correlated with traditional cardiovascular risk factors, high-sensitivity C-reactive protein (hs-CRP), and coronary artery calcium (CAC) measured by electron beam computed tomography. RESULTS: Higher MCP-1 levels were associated with older age, white race, family history of premature coronary disease, smoking, hypertension, diabetes, hypercholesterolemia, and higher levels of hs-CRP (p < 0.01 for each). Similar associations were observed between MCP-1 and risk factors in the subgroup of participants without detectable CAC. Compared with the subjects in the lowest quartile of MCP-1, the odds of prevalent CAC (CAC score >/=10) for subjects in the second, third, and fourth quartiles were 1.30 (95% confidence interval [CI] 0.99 to 1.73), 1.60 (95% CI 1.22 to 2.11), and 2.02 (95% CI 1.54 to 2.63), respectively. The association between MCP-1 and CAC remained significant when adjusted for traditional cardiovascular risk factors, but not when further adjusted for age. CONCLUSIONS: In a large population-based sample, plasma levels of MCP-1 were associated with traditional risk factors for atherosclerosis, supporting the hypothesis that MCP-1 may mediate some of the atherogenic effects of these risk factors. These findings support the potential role of MCP-1 as a biomarker target for drug development.
Authors: Diederik F van Wijk; Sander I van Leuven; Manjinder S Sandhu; Michael W Tanck; Barbara A Hutten; Nicholas J Wareham; John J P Kastelein; Erik S G Stroes; Kay-Tee Khaw; S Matthijs Boekholdt Journal: Arterioscler Thromb Vasc Biol Date: 2010-04-29 Impact factor: 8.311
Authors: Benjamin M Scirica; Marc S Sabatine; Petr Jarolim; Sabina A Murphy; James L de Lemos; Eugene Braunwald; David A Morrow Journal: Eur Heart J Date: 2010-12-22 Impact factor: 29.983
Authors: Ann B Nguyen; Anand Rohatgi; Christine K Garcia; Colby R Ayers; Sandeep R Das; Susan G Lakoski; Jarett D Berry; Amit Khera; Darren K McGuire; James A de Lemos Journal: Arterioscler Thromb Vasc Biol Date: 2011-08-04 Impact factor: 8.311
Authors: Anand Rohatgi; Andrew W Owens; Amit Khera; Colby R Ayers; Kamakki Banks; Sandeep R Das; Jarett D Berry; Darren K McGuire; James A de Lemos Journal: Arterioscler Thromb Vasc Biol Date: 2009-10 Impact factor: 8.311
Authors: Amit Khera; Gloria L Vega; Sandeep R Das; Colby Ayers; Darren K McGuire; Scott M Grundy; James A de Lemos Journal: J Clin Endocrinol Metab Date: 2009-06-30 Impact factor: 5.958
Authors: Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar Journal: Am J Physiol Heart Circ Physiol Date: 2019-02-01 Impact factor: 4.733